PeterAKaufmanMD

Oncology • Burlington, VT

Breast Cancer, Hematologic Oncology

Associate Professor of Medicine, Dartmouth Medical School

Join to view full profile

Dr. Kaufman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kaufman's full profile

Already have an account?

Office
Beaumont Ave
UVM Cancer Center
Burlington, VT 05403
Phone+1 603-653-6181

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 1986 - 1989
Duke University HospitalResidency, Internal Medicine, 1983 - 1986
New York University School of MedicineClass of 1983

Certifications & Licensure

VT State Medical License 1993 - 2026
NH State Medical License 1992 - 2020
NC State Medical License 1987 - 2015
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial.
Kevin Kalinsky, Giampaolo Bianchini, Erika Hamilton, Stephanie L Graff, Kyong Hwa Park
Journal of Clinical Oncology. 2024-12-18
2 citations
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Grow...
Komal L Jhaveri, Elgene Lim, Rinath Jeselsohn, Cynthia X Ma, Erika P Hamilton
Journal of Clinical Oncology. 2024-12-10
A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study.
Patrick Neven, Nicole Stahl, Maria Vidal, Miguel Martín, Peter A Kaufman
Clinical Cancer Research. 2024-12-02

Lectures

Balixafortide (a CXCR4 antagonist) + eribulin in HER2-negative metastatic breast cancer (MBC): Survival outcomes of the phase I trial.
ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019

Press Mentions

Breast Cancer: What We Know TodayJune 2nd, 2022
Laekna Therapeutics Announces Dosing of First Patients in the U.S. And China in Phase Ib/III Study of Afuresertib in Combination with Fulvestrant in HR+/HER2- Breast CancerMay 26th, 2022
UVM Students Contribute to Groundbreaking Cancer ResearchJune 9th, 2021